I agree Eqz. I was just responding to what another poster said....

I agree Eqz. I was just responding to what another poster said. I do think $2.00 is ultra conservative but all hinges on up coming announcements. If Jansen does go ahead with a collaboration, then $3.00 or more is possible l think. My gut feeling is that they probably will if the Phase 2 results confirm Promarker D predictability. I base this on the fact that Ivokana is expensive, so they will need a tool to convince patients and Doctors that the expense is justified. Hence the original invitation by Jansen for PIQ to join the Phase one clinical trial. Possible Cardiogenic benefits, Endometriosis trials and others PIQ is working on will add a lot of company value as well. Irrespective of this, just the Diabetes testing and the continual need to have run repeatedly for the life of the patient, means Promarker D will potentially be a huge money earner alone. Someone ran some numbers suggesting if we only captured half the global market, the current SP would be well north of $ 10.00. Not much income from the roll put of tests yet, but this will potentially change quickly as the conservative medical profession learns about the benefits of Promarker D. The share market will extropalate likely future earnings and re-rate the company achordingly. This has not happened as we are still below the radar of most investors and practically every Doctor. When a re-rate happens as it inevitably will, this could rocket to a much higher value very very quickly. Just my opinion though. The past months gains have been terrific.